Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
IMvigor210
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)
- NCT02951767 ↗
- Completed
- Hoffmann-La Roche
- Deep
We haven't built an HCP commentary report on IMvigor210 (atezolizumab in locally advanced or metastatic urothelial bladder cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on IMvigor210 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 27 | |
| Podcasts | 5 |
The trial
ClinicalTrials.gov- Official title
- A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Bladder Cancer
- Interventions
- Atezolizumab
- Arms
- Cohort 1: Treatment-naive Cisplatin Ineligible Participants · Experimental
- Enrollment
- 119
- Primary outcomes
- Percentage of Participants With a Confirmed Objective Response of Complete Response (CR) or Partial Response (PR) as Assessed by the Independent Review Facility (IRF) According to RECIST v1.1
- Sponsor
- Hoffmann-La Roche
- Start
- May 31, 2014
- Primary completion
- Jul 4, 2016
- Results posted
- Yes
- Registry record
- NCT02951767 · updated Mar 28, 2024
Publications
linked from the registry- Szabados B, Ponz-Sarvise M, Machado R, Saldana D, Kadel EE, Banchereau R, Bouquet F, Garmhausen M, Powles T, Schroder C; imCORE Working Group of Early Career Investigators (imFLAME). Clinico-Genomic Characterization of Patients with Metastatic Urothelial Carcinoma in Real-World Practice Identifies a Novel Bladder Immune Performance Index (BIPI). Clin Cancer Res. 2022 Sep 15;28(18):4083-4091. doi: 10.1158/1078-0432.CCR-22-0200. PubMed 35877091
- Vander Velde N, Guerin A, Ionescu-Ittu R, Shi S, Wu EQ, Lin SW, Hsu LI, Saum KU, de Ducla S, Wang J, Li S, Thastrom A, Liu S, Shi L, Leppert JT. Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the Veterans Health Administration. Eur Urol Oncol. 2019 Feb;2(1):12-20. doi: 10.1016/j.euo.2018.07.003. Epub 2018 Aug 4. PubMed 30929841